TX Houston의 버킷 림프종 임상 시험
버킷 림프종 관련 연구 20개가 Houston 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
피험자 모집 중1/2상
- Research Site, Houston
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
피험자 모집 중2상
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
피험자 모집 중3상
- Texas Children's Hospital, Houston
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
피험자 모집 중3상
- Houston Methodist Hospital, Houston
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
피험자 모집 중1/2상
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
피험자 모집 중관찰 연구
- Texas Children's Hospital, Houston
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
피험자 모집 중2상
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
피험자 모집 중2상
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
피험자 모집 중1/2상
- University of Texas MD Anderson Cancer Center, Houston
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
피험자 모집 중3상
- The University of Texas MD Anderson Cancer Center, Houston
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
피험자 모집 중1/2상
- Research Site, Houston
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
피험자 모집 중3상
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
피험자 모집 중2상
- Baylor Texas Children's Hospital, Houston
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
피험자 모집 중1/2상
- MD Anderson Cancer Center, Houston
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
피험자 모집 중2상
- M D Anderson Cancer Center, Houston
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
피험자 모집 중1/2상
- M D Anderson Cancer Center, Houston
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
피험자 모집 중2상
- M D Anderson Cancer Center, Houston
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
피험자 모집 중1상
- University of Texas MD Anderson Cancer Center, Houston
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
피험자 모집 중2상
- The University of Texas M. D. Anderson Cancer Center, Houston
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
피험자 모집 중1상
- MD Anderson Cancer Center, Houston
다른 도시의 버킷 림프종 시험
- Milwaukee, WI연구 16개
- Chicago, IL연구 15개
- Philadelphia, PA연구 15개
- Seattle, WA연구 14개
- Atlanta, GA연구 13개
- New York City, NY연구 13개
- Cincinnati, OH연구 13개
- Los Angeles, CA연구 10개
- Baldwin Park, CA연구 10개
- Aurora, CO연구 10개
- Durham, NC연구 10개
- Kansas City, MO연구 10개
Houston의 다른 연구
- 비소세포폐암연구 143개
- 유방암연구 126개
- 암 (전체)연구 124개
- 대장직장암연구 101개
- 전이성 암연구 100개
- 난소암연구 90개
- 급성 골수성 백혈병연구 88개
- 폐암연구 78개
- 전립선암연구 73개
- 자궁내막암연구 69개
- 흑색종연구 61개
- 췌장암연구 59개
ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.